ZIM
JANX icon

Zacks Investment Management’s Janux Therapeutics JANX Stock Holding History

Zacks Investment Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,968
Closed -$877K – 804
2025
Q2 		$877K Sell
37,968
-154
-0.4% -$4.06K 0.01% 421
2025
Q1 		$1.03M Sell
38,122
-51
-0.1% -$1.92K 0.01% 404
2024
Q4 		$2.04M Sell
38,173
-3,960
-9% -$209K 0.02% 331
2024
Q3 		$1.91M Buy
42,133
+3,360
+9% +$146K 0.02% 348
2024
Q2 		$1.62M Sell
38,773
-2,146
-5% -$101K 0.02% 317
2024
Q1 		$1.54M Sell
40,919
-17,885
-30% -$389K 0.02% 351
2023
Q4 		$631K Buy
+58,804
New +$509K 0.01% 437

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Zacks Investment Management's JANX Position: Q3 2025 in Review

Zacks Investment Management sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 37,968 shares — an estimated $877K sold.

Zacks Investment Management first reported a position in JANX in Q4 2023 and held it in 7 quarters. The position peaked at $2.04M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Zacks Investment Management reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 37,968 Janux Therapeutics shares in Q3 2025, an estimated $877K.
  • Zacks Investment Management first reported a position in Janux Therapeutics in Q4 2023 and held it in 7 quarters.
  • Zacks Investment Management's Janux Therapeutics position peaked at $2.04M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.